Category Archives: Corporate

Latest From Corporate

Bringing Hope to Patients

Jim Greenwood

No-one expected Hope Bartley to survive after she was born three months early. Thanks to extraordinary biotech medicine, she did. Alena Galan, age 14, is one of only a few thousand patients with a rare disease called MPS. Thanks to the hard work of leading biotech scientists and the approval of a new treatment, she now has a chance to lead a normal life. Lori Lober experienced the unthinkable when she was diagnosed with Stage Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

2011: A Pivotal Year for Biotechnology

Jim Greenwood

Biotechnology continues to hold the greatest promise to address many of the most critical issues facing our world. Continued innovation will lead to breakthrough new and improved cures and treatments for patients living with debilitating diseases such as cancer, HIV/AIDS, diabetes and Parkinson’s; enhanced agricultural products to feed a growing global population while protecting the environmental health of our planet; vaccines to protect against bioterrorism; and revolutionary biofuels. The ability of BIO members to continue Read More >

Jim's Corner  |  1 Comment  |  Email This Post
Tags: , ,

Continued progress in advanced biofuels relies on the RFS

Jim Greenwood

There is widespread agreement among experts, policy makers and the public that the United States must overcome its addiction to fossil fuels to protect the environment and for reasons of national security. As in any addiction, interventions are necessary to break bad habits. Fortunately, in 2007 Congress expanded the Renewable Fuel Standard (RFS), requiring increased production and use of renewable fuels from multiple sources. American companies are making steady progress in creating advanced plant-based fuels. Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Raising the Stakes in Biotech

JimGreenwood

Small biotech companies continue to struggle to obtain funding as capital markets remain tight. The S&P downgrade may create even tighter credit markets and raise the cost of available credit, for small and large companies. To the extent that the downgrade leads capital flows out of the U.S., that hurts biotech. Biotech’s contributions to the world are critically needed. Our industry holds great promise for curing and treating many prevalent diseases, such as Alzheimer’s, cancer, Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

FDA: How can we improve it?

Stephen Sherwin MD

By Stephen Sherwin, Former Chairman of BIO As Congress and the President work together to hammer out a new, national economic roadmap, it is important to point out to those working in, and interested in, our industry that we too have recently assembled a roadmap – one designed to fully realize the promise our industry holds for people everywhere. Several weeks ago, at the 2011 BIO International Convention in Washington, DC, BIO unveiled its first ever 5 Read More >

Corporate  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,